1 / 66

Management of OPC Poisoning: Current Vs Evidence-Based Practice

Management of OPC Poisoning: Current Vs Evidence-Based Practice. Background. Diseases- Neither Preventable Nor Curable. e.g., MS Preventable but Not Curable e.g., Lung cancer Preventable and Curable e.g. OPC poisoning More than 200 000 deaths each year in developing countries

alyn
Télécharger la présentation

Management of OPC Poisoning: Current Vs Evidence-Based Practice

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Management of OPC Poisoning: Current Vs Evidence-Based Practice

  2. Background Diseases- Neither Preventable Nor Curable. e.g., MS Preventable but Not Curable e.g., Lung cancer Preventable and Curable e.g. OPC poisoning • More than 200 000 deaths each year in developing countries • Mortality from severe poisoning is high (>10%) BMJ 2007;334:629-34

  3. Acetylcholinesterase (AChE) AChE is an enzyme that degrades the neurotransmitter acetylcholine AChE ↗

  4. Mechanism of toxicity of organophosphorus compounds

  5. Mechanism of toxicity of organophosphorus compounds

  6. Some OP available in Bangladesh Dimethyl compounds ( ageing 3.7 hours) • Malathion • Dichlorvos • Dimethoat • Fenthion Diethyl compounds ( 31 hrs) • Chlorpyrifos • Diazinon • Parathion • Quinalphos

  7. Pathogenesis Inhibition of acetyl cholinesterase leads to the accumulation of acetylcholine at cholinergic synapses, interfering with normal function of the autonomic, somatic, and central nervous systems. This produces a range of clinical manifestations, known as the acute cholinergic crisis O P C C N S Acetyl Cholinesterase Breakdown products N I C Ach OX IMES M U S Atropine

  8. Signs and symptoms of OPC poisoning Four clinical syndromes have been described: • Acute cholinergic syndrome (most common) • Sub acute proximal weakness (Intermediate syndrome) • Organophosphate induced delayed neuropathy (OPIDN) • Chronic organophosphate induced neuropsychiatric disorder (COPIND)

  9. Grading of severity of poisoning • Clinical Grading • Biochemical Grading

  10. Grading of severity of poisoning Clinical grading: based on- 1.Miosis 2.Fasciculation 3.Respiratory Rate 4.Bradycardia 5.Level of consciousness *Mild(0-3), * Moderate(4-7), *Severe(8-11)

  11. Grading of severity of poisoning Biochemical Grading: Red cell cholinesterase activity (% normal) Grade • 20-50% Mild • 10-20% Moderate • <10% Severe

  12. Management of OPC Poisoning Hospitalization/ ICU • Initial stabilization • Reduction of exposure • Administration of specific antidote • Supportive treatment

  13. Initial Stabilization of the patient • Clear airway and • Adequate ventilation because the patient with acute organophosphate poisoning (ACC) commonly presents with respiratory distress. • Oxygen- high flow ?? Prior to atropinization • Circulation- iv access

  14. Decontamination • Dermal spills—wash pesticide spills from the patient with soap and water and remove and discard contaminated clothes, shoes and any other material made from leather • Gastric lavage—consider for presentations within 1 or 2 hours, when the airway is protected. A single aspiration of the gastric contents may be as useful as lavage • Activated charcoal without cathartic—50 g may be given orally or nasogastrically to patients who are cooperative or intubated, particularly if they are admitted within one or two hours or have sever toxicity

  15. Investigations ECG: torsades de pointes Oxygen saturation Blood gas analysis Renal and hepatic function Electrolytes Glucose Amylase

  16. Antidotes in the treatment of OPC poisoning • Atropine- Reverses the muscarinic features. • Oxime-    Reactivate cholinesterase and reverses the nicotinic features.

  17. Dosage regimens of Atropine • Repeated doses of atropine should be administered until signs of atropinisation appear. • Conventional Vs Evidence-Based Practice • Try test dose of atropine

  18. Dosage regimens of Atropine Test dose of Atropine: It is preferable to initiate the antidote therapy with a 'test dose' of parenteral atropine-sulphate (1.2 mg in adults and 0.01 mg/kg in children IV) • This therapeutic test provides a measure of severity of organophosphate poisoning. • If the signs of atropinisation occur rapidly, it is unlikely that the poisoning is severe or it may not be OPC poisoning.

  19. Dosage regimens of Atropine: Conventional Practice • Dosage regimens are usually designed according to the severity of poisoning and to the signs of atropinisation • 2-5 mg every 5-10-15 minutes. After initial atropinization, maintain the atropinization by reducing the dose or increasing the duration between doses of atropine • 1 ampoule contains 0.6 mg atropine sulphate

  20. Dosage regimens of Atropine: Alternative regimen: ??? Evidence-Based • Give first dose atropine immediately 1.8–3 mg (three to five 0.6 mg ampoules) rapidly IV into a fast-flowing IV drip • Don’t delay starting atropine if oxygen is unavailable BMJ 2007;334:629-34, J Med Toxicol 2012 Feb17 online

  21. Assess – is the patient atropinised? After 3-5 minutes of atropine administration record followings :- (1) air entry into lungs: clear chest (2) blood pressure: SBP > 80 mm Hg (3) heart rate: > 80 beats/ min (4) Pupil: no longer pinpoint (5) Dry axillae Contd.

  22. Assess – is the patient atropinised? • Mark them on an OPC observation sheet • A uniform improvement in most of the five parameters is required, not improvements in just one. • Pupil dilatation is sometimes delayed. and the other parameters may improve more rapidly, it is reasonable to observe air entry on chest auscultation, heart rate, and blood pressure as the main parameters for adequate atropinisation. • When all the parameters are satisfactory, the patient has received enough atropine and is “atropinised”

  23. Giving fluids/ IV channel Two IV drips should be set up • One for fluid and drugs. Give 500–1000 ml (10–20 ml/kg) of normal saline • Other for atropine

  24. Continuation of bolus atropine loading to reach atropinisation • If after 3–5 min a consistent improvement across the five parameters has not occurred. Then • Continue to double the dose every 3-5 minutes until atropinisation has been achieved • Do not simply repeat the initial dose of atropine Atropinise the patient as quickly as possible

  25. Atropine treatment after atropinization • Once atropinized set up an infusion using one of the two IV cannulae • In the infusion, give 10–20% of the total atropine that was required to load the patient every hour

  26. Observation of the patient: Themost important • Follow up every 15 min with five parameter • If recurrence of bronchospasm or bradycardia, give further boluses of atropine • Once the patient settled then follow up hourly for the first 6 hours to check that the atropine infusion rate is sufficient and that there are no signs of atropine toxicity • As the required dose of atropine falls, observation for recurrence of cholinergic features can be done less often (every 2–3 hours) • However, regular observation is still required to spot patients at risk of, and going into, respiratory failure

  27. Atropine toxicity • Central effect • Hyperpyrexia • Restlessness • Anxiety • Excitement • Hallucination • Delirium • Mania • Cerebral depression • Coma • Peripheral effect • Dry mouth • Mydriasis ? • Blurred vision • Hot dry skin • Tachycardia ? • Look for retention of urine 

  28. Atropine toxicity • Hot as a hare • Blind as a bat • Dry as a bone • Red as a beet • Mad as a hen

  29. Management of Atropine toxicity • Stop the atropine infusion • Check again after 30 min to see whether the features of toxicity have settled • If not, continue to review every 30 min or so • When they do settle, restart at 70–80% of the previous rate • The patient should then be seen frequently to ensure that the new infusion rate has reduced the signs of atropine toxicity without permitting the reappearance of cholinergic signs

  30. Oximes Action of Oximes: • Oximes are the specific biochemical antidote for OPC induced intoxication • They reactivate the inhibited cholinesterase • Oximes ameliorate the nicotinic, muscarinic & C.N.S. effects

  31. Pralidoxime Praliodoxime is used in conjunction with atropine in moderate and severe poisoning. It has a strong synergistic effect with atropine and provides a dose sparing effect on the amount of atropine

  32. Dosage regimen of pralidoxime Loading dose 30 mg/kg of pralidoxime over 10–20 min, followed by continuous infusion of 8–10 mg/kg per hour until clinical recovery (12 hours after stopping administration of atropine or once butyrylcholinesterase is noted to increase)

  33. Obidoxime • Currently obidoxime has been introduced. It crosses blood brain barrier more than pralidoxime • Where obidoxime is available, a loading dose of 250 mg is followed by an infusion giving 750 mg every 24 hours

  34. Advantages of rapid incremental dose atropinization followed by atropine infusion • Reduces morbidity and mortality • Shortens the length of hospital stay • Requires a shorter time to atropinization • Requires less frequent follow-up • Maintain sustain blood levels of atropine • Lower incidence of atropine toxicity • Less IMS

  35. High Quality Supportive Care • Management of respiratory insufficiency • Maintenance of circulation • Treatment of convulsion and other complications • Fluid and electrolyte balance • Control of infections (aspiration pneumonia) • Maintenance of nutrition • Control of body temperature

  36. Respiratory Failure • Management of respiratory failure represents the corner stone of treatment. • Artificial ventilation should be started at the first sign of respiratory failure. • For pulmonary edema, high concentration 02 and diuretic should be used. • Morphine and aminophyline should be avoided. • Broad spectrum antibiotic is used as prophylactic measure for aspiration pneumonia.

  37. Active Cooling and Sedation • Lay a towel soaked with water over the patient's chest and place in a fan's airflow. • Benzodiazepines Benzodiazepines are usually given intravenously as required for agitation or seizures—with doses starting at: 5-10 mg diazepam (0.05-0.3 mg/kg/dose), lorazepam 2-4 mg (0.05-0.1 mg/kg/dose), or midazolam 5-10 mg (0.15-0.2 mg/kg/dose)

  38. Follow up of the patient • Vital signs • Signs of Atropinisation • Effect of oxime • Toxicity of atropine and oxime • RBC and plasma AChE level • Recurrence of symptoms on withdrawal of antidote • Restart the treatment promptly if recurrence occurs • Patient’s general condition

  39. Disposition • Consider discharge from ICU to medical ward once stable for 12 hours after oxime • Stable for 48 hours after discharge from intensive care unit- consider disposition and psychiatric review

  40. Cause of Death in OPC poisoning 1. Immediate death: • Seizures. • Complex ventricular arrhythmias. 2. Death within 24 hours: - Acute cholinergic crisis in untreated severe case -Respiratory failure. 3. Death within 10 days of poisoning: - intermediate syndrome. Contd.

  41. Cause of Death in OPC poisoning 3. Death within 10 days of poisoning: - intermediate syndrome. • Late death: - Secondary to ventricular arrhythmias, including Torsades de Pointes, which may occur up to 15 days after acute intoxication.

  42. Prognosis of Organophosphorus Insecticide Poisoning • Deaths usually occur within the first 24 hours in untreated cases and within 10 days in treatment failure cases. • If there has been no anoxic brain damage, recovery will usually occur within 10 days, although there may be residual sequelae.

  43. Factors related to death in OPC poisoning • Amount ingested • Delay in hospitalization • Delay in starting treatment • Neglected • Lack of standardized treatment protocol • Atropine toxicity • Lack of frequent monitoring • Lack of ICU support including financial constrain • Treatment seeking behavior

  44. Should We Let Her Die?

  45. WE Should Try To Save Her THANK YOU ALL

  46. THANK YOU THANK YOU ALL

  47. Target end-points for atropine therapy • Clear chest on auscultation with no wheeze • Heart rate >80 beats/min • Pupils no longer pinpoint • Dry axilla • Systolic blood pressure >80 mmHg

  48. Signs of Atropinisation: • Mydriasis • Tachycardia. • Flushing • Dry mouth & nose • Anhydrosis • Bronchodilation

More Related